- Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
-
Oh TJ, Jung HS, Bae JH, Kim YG, Park KS, Cho YM, Park KS, Kim SY
- KMID: 2158036
- J Korean Med Sci.
- 2013 Jun;28(6):881-887.
- doi: 10.3346/jkms.2013.28.6.881
We investigated characteristics associated with the efficacy of dipeptidyl peptidase-4 inhibitors (DPP4i) in Korean patients with type 2 diabetes. We reviewed medical records of 477 patients who had taken sitagliptin... -
- CITED
-
- Close
- SHARE
-
- Close
- Use of Bortezomib as Anti-Humoral Therapy in Kidney Transplantation
-
Yang KS, Jeon H, Park Y, Jo IH, Kim JI, Moon IS, Choi BS, Park CW, Yang CW, Kim YS, Chung BH
- KMID: 1786104
- J Korean Med Sci.
- 2014 May;29(5):648-651.
- doi: 10.3346/jkms.2014.29.5.648
This study aimed to investigate the effect of bortezomib in the desensitization and treatment of acute antibody mediated rejection (AAMR) in kidney transplantation. Nine patients who received bortezomib therapy for... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
-
Lee HS, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS, The Korean Multiple Myeloma Working Party (KMMWP)
- KMID: 2158005
- J Korean Med Sci.
- 2013 Jan;28(1):80-86.
- doi: 10.3346/jkms.2013.28.1.80
Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival.... -
- CITED
-
- Close
- SHARE
-
- Close
